Posted On: 09/30/2014 8:53:09 PM
Post# of 273351
Alexion Pharmaceuticals (ALXN) 165.82 $ALXN
Growth Prospects Still Solid At Alexion Pharmaceuticals
at Investor's Business Daily - 2 hrs 28 mins ago
Alexion Pharmaceuticals (ALXN) may be a one-hit wonder, but it's a very lucrative one. Despite a small market for its only marketed drug, Soliris, Alexion generated $1.55 billion in sales in 2013, up 37% from 2012. This year, sales are seen rising...
WuXi PharmaTech Announces Appointment of William R. Keller to Board
PR Newswire - Tue Sep 30, 7:00AM CDT
WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced the appointment of William Robert Keller as an independent director on the Board of Directors. He will serve on the Strategy Committee.
Investors Can Sell Stocks Before A 7% Or 8% Loss
at Investor's Business Daily - Mon Sep 29, 4:34PM CDT
Leading stocks that break out of bases are the primary targets of CAN SLIM investors. Yet while some breakout stocks go on to big gains, others may fizzle. That's why investors should always cut losses at 7% or 8%, without question. But sometimes...
Insider Trading Alert - MWV, RSG And ALXN Traded By Insiders
at The Street - Mon Sep 29, 9:15AM CDT
Stocks with insider trader activity include MWV, RSG and ALXN
Acquisitions, Senior Level Promotions, Public Offering, and Drug Approvals - Research Reports on Acorda, Alexion, Envision, Lilly and Avanir
PR Newswire - Mon Sep 29, 7:50AM CDT
Today, Analysts Review released its research reports regarding Acorda Therapeutics, Inc. (NASDAQ: ACOR), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Envision Healthcare Holdings, Inc. (NYSE: EVHC), Eli Lilly and Company (NYSE: LLY) and Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6820-100free.
Technology Stocks Slide But Other Sectors Hold Up Better
at Investor's Business Daily - Thu Sep 25, 5:55PM CDT
A harsh sell-off in the market Thursday did not spare many stocks in Your Weekly Review. Nearly every stock on the screen closed lower, and the selling affected certain sectors more than others. However, few leaders triggered outright sell signals....
Stock Market News for September 25, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 9:10AM CDT
Markets rebounded on Wednesday after taking losses in three straight sessions
After Yesterday's Rally of 6.32% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Sep 24, 3:55PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $158.67 to a high of $168.98. Yesterday, the shares gained 6.3%, which took the trading range above the 3-day high of $163.50 on volume of 1.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Stocks End Skid; Vertex, Alexion Lead Biotech Rebound
at Investor's Business Daily - Wed Sep 24, 3:16PM CDT
The major averages rose Wednesday, erasing most of the week's losses, aided by dovish comments from a top Federal Reserve official. The Nasdaq rose 1%, the Dow Jones industrial average 0.9% and the S&P 500 0.8%. Volume was mixed, rising 6% on the...
Stocks Up In Afternoon; Hasbro Jumps On Disney Deal
at Investor's Business Daily - Wed Sep 24, 2:05PM CDT
The major averages were hitting fresh intraday highs in late afternoon trading Wednesday, spurred by dovish comments from a top Federal Reserve policymaker. The Nasdaq and the Dow Jones industrial average each added 0.9%, while the S&P 500 picked up...
Stocks Hold Solid Gains; CyberArk Soars In Debut
at Investor's Business Daily - Wed Sep 24, 12:20PM CDT
Major averages held solid gains in early afternoon trading Wednesday. The Nasdaq added 0.6%, the Dow Jones industrial average rose 0.5% and the S&P 500 picked up 0.4%. NYSE volume was tracking slightly higher than Wednesday. Nasdaq volume was...
Biotech Stock Roundup: Auxilium an Acquisition Target, Amgen Submits another BLA - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Sep 24, 10:05AM CDT
Auxilium Pharmaceuticals' (AUXL) shares soared almost 45% on a $2.2 billion acquisition proposal from Endo.
Biopharmaceutical and Vaccine Production Markets to 2018
M2 - Tue Sep 23, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h2pzn6/biopharmaceutical) has announced the addition of the "Biopharmaceutical and Vaccine Production Markets" report to their offering. Though biotechnology has created many new therapies and vaccines - including products to treat cancer, diabetes, HIV/AIDS and autoimmune disorders - there are still huge challenges during the final stages of clinical drug testing for new biopharmaceuticals, as manufacturers decide when and how to risk production capital to upscale while anticipating FDA or EMA approval. During the past five years, estimates for biopharmaceuticals have varied widely as analysts and producers have juggled the promise of new drugs with the technological and financial risks of manufacturing them efficiently. Biopharmaceutical and Vaccine Production Markets examines the total biopharmaceutical manufacturing market, including in its estimates all costs related to biopharmaceutical and vaccine production. It includes the following useful information for business planning: - Market Forecasts and Estimates of Biopharmaceutical Manufacturing Costs - Vaccine Production Estimates - Trend Discussion - Production Methods - The Competitive Environment, including Contract Manufacturing and Outsourcing - Regulation of the Market - Company Profiles The report contains production segmentations for the mammalian cell, microbial cell, monoclonal antibody, other recombinant protein, vaccine, and insulin manufacturing markets, with forecasts to 2018. The current competitive environment is noted, listing selected biopharmaceutical contract manufacturers, selected top-selling biopharmaceuticals, selected Asian biomanufacturing contract manufacturing organizations (CMOs), the top 10 biopharma companies based on 2012 biopharma revenues, and the top manufacturers by global biopharmaceutical manufacturing capacity. Report profiles of major contract manufacturers: - Lonza AG - Boehringer Ingelheim GmbH - FUJIFILM Diosynth Biotechnologies - Sandoz - Royal DSM - Rentschler Biotechnologie - Celonic - BIOMEVA GmbH - ProBioGen AG - Baxter BioPharma Solutions/Baxter Bioscience Major biologics firms : - Amgen - Genentech/Roche - AbbVie Inc. (Abbott) - Biogen Idec - Regeneron Pharmaceuticals - Alexion Pharmaceuticals - Crucell /Johnson & Johnson - GlaxoSmithKline - Merck & Co. Inc - Novartis - Pfizer - Sanofi Pasteur Other contract manufacturers profiled - AAIPharma - A-Bio Pharma Pte Ltd. - ABL, Inc. - Affinity Life Sciences, Inc. - Ajinomoto Aminoscience, LLC - Alliance Medical Products, Inc. - Alpha Biologics - Biotecnol - Boston Mountain Biotech - Glycobia - Sutro Biopharma Key Topics Covered: - Executive Summary - Commercial Production - Forecasts - Regulation - Competitive Environment - Patents - Geography - Profiles For more information visit http://www.researchandmarkets.com/research/h2...maceutical
Is Illumina (ILMN) Worth Adding to Your Portfolio? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 2:20PM CDT
Recently, Zacks Investment Research upgraded Illumina Inc. (ILMN) to a Zacks Rank #1 (Strong Buy).
IBD 50 Stocks Setting Up, Including These 5 Medicals
at Investor's Business Daily - Fri Sep 19, 6:36PM CDT
Recent volatility in the stock market, including an outlook shift to uptrend under pressure and back to a confirmed uptrend, may have rattled investors' nerves. But it's also helped set up new potential entries as some leading stocks slipped into buy...
Paediatric Patients with Hypophosphatasia Receiving Investigational Asfotase Alfa Had Sustained Improvements in Growth and Physical Function
Business Wire - Fri Sep 19, 2:45AM CDT
Alexion Pharmaceuticals today announced that researchers presented data from the open-label extension phases of two Phase 2 studies of asfotase alfa, an investigational enzyme replacement therapy, in paediatric patients with hypophosphatasia (HPP).(1,2) In the ongoing studies, researchers observed sustained improvements in growth, strength, physical function, and other key measures in paediatric patients with HPP who were treated with asfotase alfa for up to three years. HPP is a genetic, chronic and progressive ultra-rare metabolic disease that can lead to ongoing damage to multiple vital organs, destruction and deformity of bones, and premature death.(3-7) Data were presented today at the 53rd Annual European Society for Paediatric Endocrinology (ESPE) Meeting in Dublin, Ireland, following a presentation of similar data earlier this month at the American Society for Bone and Mineral Research (ASBMR) 2014 Annual Meeting.(8,9)
Alexion Strengthens and Broadens Its Executive Leadership Team
Business Wire - Wed Sep 17, 6:30AM CDT
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced key measures to strengthen and broaden its executive leadership team in line with the Company's expanding global mission to develop and commercialize life-transforming therapies for patients with severe and rare disorders.
Alexion Pharmaceuticals Falls 1.41% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Sep 15, 4:21PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $157.30 to a high of $162.02. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $161.00 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Nasdaq Falls Hard, But Apple Resilient On iPhone Orders
at Investor's Business Daily - Mon Sep 15, 1:55PM CDT
The Dow Jones industrial average and S&P 500 traded in a tight range Monday, but the Nasdaq took a beating as profit-taking hit several recent highfliers. The Nasdaq moved off lows but still fell 0.9%, hurt by weakness in Tesla Motors (TSLA). Shares...
Growth Prospects Still Solid At Alexion Pharmaceuticals
at Investor's Business Daily - 2 hrs 28 mins ago
Alexion Pharmaceuticals (ALXN) may be a one-hit wonder, but it's a very lucrative one. Despite a small market for its only marketed drug, Soliris, Alexion generated $1.55 billion in sales in 2013, up 37% from 2012. This year, sales are seen rising...
WuXi PharmaTech Announces Appointment of William R. Keller to Board
PR Newswire - Tue Sep 30, 7:00AM CDT
WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced the appointment of William Robert Keller as an independent director on the Board of Directors. He will serve on the Strategy Committee.
Investors Can Sell Stocks Before A 7% Or 8% Loss
at Investor's Business Daily - Mon Sep 29, 4:34PM CDT
Leading stocks that break out of bases are the primary targets of CAN SLIM investors. Yet while some breakout stocks go on to big gains, others may fizzle. That's why investors should always cut losses at 7% or 8%, without question. But sometimes...
Insider Trading Alert - MWV, RSG And ALXN Traded By Insiders
at The Street - Mon Sep 29, 9:15AM CDT
Stocks with insider trader activity include MWV, RSG and ALXN
Acquisitions, Senior Level Promotions, Public Offering, and Drug Approvals - Research Reports on Acorda, Alexion, Envision, Lilly and Avanir
PR Newswire - Mon Sep 29, 7:50AM CDT
Today, Analysts Review released its research reports regarding Acorda Therapeutics, Inc. (NASDAQ: ACOR), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Envision Healthcare Holdings, Inc. (NYSE: EVHC), Eli Lilly and Company (NYSE: LLY) and Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6820-100free.
Technology Stocks Slide But Other Sectors Hold Up Better
at Investor's Business Daily - Thu Sep 25, 5:55PM CDT
A harsh sell-off in the market Thursday did not spare many stocks in Your Weekly Review. Nearly every stock on the screen closed lower, and the selling affected certain sectors more than others. However, few leaders triggered outright sell signals....
Stock Market News for September 25, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 9:10AM CDT
Markets rebounded on Wednesday after taking losses in three straight sessions
After Yesterday's Rally of 6.32% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Sep 24, 3:55PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $158.67 to a high of $168.98. Yesterday, the shares gained 6.3%, which took the trading range above the 3-day high of $163.50 on volume of 1.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Stocks End Skid; Vertex, Alexion Lead Biotech Rebound
at Investor's Business Daily - Wed Sep 24, 3:16PM CDT
The major averages rose Wednesday, erasing most of the week's losses, aided by dovish comments from a top Federal Reserve official. The Nasdaq rose 1%, the Dow Jones industrial average 0.9% and the S&P 500 0.8%. Volume was mixed, rising 6% on the...
Stocks Up In Afternoon; Hasbro Jumps On Disney Deal
at Investor's Business Daily - Wed Sep 24, 2:05PM CDT
The major averages were hitting fresh intraday highs in late afternoon trading Wednesday, spurred by dovish comments from a top Federal Reserve policymaker. The Nasdaq and the Dow Jones industrial average each added 0.9%, while the S&P 500 picked up...
Stocks Hold Solid Gains; CyberArk Soars In Debut
at Investor's Business Daily - Wed Sep 24, 12:20PM CDT
Major averages held solid gains in early afternoon trading Wednesday. The Nasdaq added 0.6%, the Dow Jones industrial average rose 0.5% and the S&P 500 picked up 0.4%. NYSE volume was tracking slightly higher than Wednesday. Nasdaq volume was...
Biotech Stock Roundup: Auxilium an Acquisition Target, Amgen Submits another BLA - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Sep 24, 10:05AM CDT
Auxilium Pharmaceuticals' (AUXL) shares soared almost 45% on a $2.2 billion acquisition proposal from Endo.
Biopharmaceutical and Vaccine Production Markets to 2018
M2 - Tue Sep 23, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h2pzn6/biopharmaceutical) has announced the addition of the "Biopharmaceutical and Vaccine Production Markets" report to their offering. Though biotechnology has created many new therapies and vaccines - including products to treat cancer, diabetes, HIV/AIDS and autoimmune disorders - there are still huge challenges during the final stages of clinical drug testing for new biopharmaceuticals, as manufacturers decide when and how to risk production capital to upscale while anticipating FDA or EMA approval. During the past five years, estimates for biopharmaceuticals have varied widely as analysts and producers have juggled the promise of new drugs with the technological and financial risks of manufacturing them efficiently. Biopharmaceutical and Vaccine Production Markets examines the total biopharmaceutical manufacturing market, including in its estimates all costs related to biopharmaceutical and vaccine production. It includes the following useful information for business planning: - Market Forecasts and Estimates of Biopharmaceutical Manufacturing Costs - Vaccine Production Estimates - Trend Discussion - Production Methods - The Competitive Environment, including Contract Manufacturing and Outsourcing - Regulation of the Market - Company Profiles The report contains production segmentations for the mammalian cell, microbial cell, monoclonal antibody, other recombinant protein, vaccine, and insulin manufacturing markets, with forecasts to 2018. The current competitive environment is noted, listing selected biopharmaceutical contract manufacturers, selected top-selling biopharmaceuticals, selected Asian biomanufacturing contract manufacturing organizations (CMOs), the top 10 biopharma companies based on 2012 biopharma revenues, and the top manufacturers by global biopharmaceutical manufacturing capacity. Report profiles of major contract manufacturers: - Lonza AG - Boehringer Ingelheim GmbH - FUJIFILM Diosynth Biotechnologies - Sandoz - Royal DSM - Rentschler Biotechnologie - Celonic - BIOMEVA GmbH - ProBioGen AG - Baxter BioPharma Solutions/Baxter Bioscience Major biologics firms : - Amgen - Genentech/Roche - AbbVie Inc. (Abbott) - Biogen Idec - Regeneron Pharmaceuticals - Alexion Pharmaceuticals - Crucell /Johnson & Johnson - GlaxoSmithKline - Merck & Co. Inc - Novartis - Pfizer - Sanofi Pasteur Other contract manufacturers profiled - AAIPharma - A-Bio Pharma Pte Ltd. - ABL, Inc. - Affinity Life Sciences, Inc. - Ajinomoto Aminoscience, LLC - Alliance Medical Products, Inc. - Alpha Biologics - Biotecnol - Boston Mountain Biotech - Glycobia - Sutro Biopharma Key Topics Covered: - Executive Summary - Commercial Production - Forecasts - Regulation - Competitive Environment - Patents - Geography - Profiles For more information visit http://www.researchandmarkets.com/research/h2...maceutical
Is Illumina (ILMN) Worth Adding to Your Portfolio? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 2:20PM CDT
Recently, Zacks Investment Research upgraded Illumina Inc. (ILMN) to a Zacks Rank #1 (Strong Buy).
IBD 50 Stocks Setting Up, Including These 5 Medicals
at Investor's Business Daily - Fri Sep 19, 6:36PM CDT
Recent volatility in the stock market, including an outlook shift to uptrend under pressure and back to a confirmed uptrend, may have rattled investors' nerves. But it's also helped set up new potential entries as some leading stocks slipped into buy...
Paediatric Patients with Hypophosphatasia Receiving Investigational Asfotase Alfa Had Sustained Improvements in Growth and Physical Function
Business Wire - Fri Sep 19, 2:45AM CDT
Alexion Pharmaceuticals today announced that researchers presented data from the open-label extension phases of two Phase 2 studies of asfotase alfa, an investigational enzyme replacement therapy, in paediatric patients with hypophosphatasia (HPP).(1,2) In the ongoing studies, researchers observed sustained improvements in growth, strength, physical function, and other key measures in paediatric patients with HPP who were treated with asfotase alfa for up to three years. HPP is a genetic, chronic and progressive ultra-rare metabolic disease that can lead to ongoing damage to multiple vital organs, destruction and deformity of bones, and premature death.(3-7) Data were presented today at the 53rd Annual European Society for Paediatric Endocrinology (ESPE) Meeting in Dublin, Ireland, following a presentation of similar data earlier this month at the American Society for Bone and Mineral Research (ASBMR) 2014 Annual Meeting.(8,9)
Alexion Strengthens and Broadens Its Executive Leadership Team
Business Wire - Wed Sep 17, 6:30AM CDT
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced key measures to strengthen and broaden its executive leadership team in line with the Company's expanding global mission to develop and commercialize life-transforming therapies for patients with severe and rare disorders.
Alexion Pharmaceuticals Falls 1.41% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Sep 15, 4:21PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $157.30 to a high of $162.02. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $161.00 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Nasdaq Falls Hard, But Apple Resilient On iPhone Orders
at Investor's Business Daily - Mon Sep 15, 1:55PM CDT
The Dow Jones industrial average and S&P 500 traded in a tight range Monday, but the Nasdaq took a beating as profit-taking hit several recent highfliers. The Nasdaq moved off lows but still fell 0.9%, hurt by weakness in Tesla Motors (TSLA). Shares...
(0)
(0)
